{"url_path":"/sec/ctxr/8-k/2026-05-08/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","accession_number":"0001213900-26-053916","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":298,"has_tables":true,"body_markdown":"false\n0001506251\n\n0001506251\n\n2026-05-04\n2026-05-04\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n**FORM 8-K**\n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of\n\nthe Securities Exchange Act of 1934\n\n \n\nDate of Report (Date of earliest event reported)\nMay 4, 2026\n\n \n\n**Citius Pharmaceuticals, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\nNevada\n\n(State or other jurisdiction of incorporation)\n\n \n\n001-38174\n \n27-3425913\n\n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n11 Commerce Drive, 1st Floor, Cranford, NJ\n \n07016\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code (908) 967-6677\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\nTitle of each class\n \nTrading Symbol(s)\n \nName of each exchange on which registered\n\nCommon stock, $0.001 par value\n \nCTXR\n \nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}